The global acute coronary syndrome market is anticipated to witness lucrative growth over the forecast period owing to increasing incidences of life style associated disorders such as of diabetes, rising level of hypertension and obesity. Acute Coronary Syndrome (ACS) may result in chest pain, vomiting or sweating and might reduce blood flow to the heart, which may lead to stroke or heart attack. Factors such as rising consumption of alcohol, cigarette and drugs are the vital drivers for this market over the forecast period. Rapid changing lifestyle coupled with change in food habits are boosting the growth of ACS market in coming seven years. Favorable government policies for early stage disease diagnosis coupled with increasing healthcare reimbursement policies are anticipated to drive the global ACS market.
For More Information on "Acute Coronary Syndrome Market Research Reports" visit - http://www.grandviewresearch.com/industry-analysis/acute-coronary-syndrome-market Antihypertensive drug is anticipated to witness significant growth over the forecast period owing to increasing incidences for stroke, high blood pressure and myocardial infarction. Due to highly efficient treatment line for blood clots, antithrombotic market is expected to show lucrative growth during the forecast period. Other drugs such as antihypertensive and statin drugs are also expected to witness lucrative growth due to increasing incidences of lifestyle associated conditions. On the basis of types, the UA (Unstable Angina) segment is likely to witness the fastest growth rate over the forecast period. NSTEMI (non-ST-elevation myocardial infarction) segment is also expected to show high growth in coming seven years due to growing number of partial heart block by blood clot. Regionally, the global ACS market was dominated by North America, in 2014. Due to huge investment in research and development coupled with rapid introduction of new drugs into the market, this region is anticipated to maintain its dominance over the forecast period. Asia Pacific region is expected to show the fastest growth in coming seven years owing to increasing healthcare expenditure, growing medical tourism and rising outsourcing activities. The global acute coronary syndrome market is highly competitive and consolidated in nature due to the presence of large number of market players. Few of them are Portal Pharmaceuticals, Dr. Reddy’s Laboratories, Sankyo, Teva Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Regeneron, AbbVie, Johnson & Johnson, GlaxoSmithKline, and Eli Lilly. Request TOC of “Acute Coronary Syndrome Market Research Reports" visit – http://www.grandviewresearch.com/industry-analysis/acute-coronary-syndrome-market/request-toc About Grand View Research Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy. Contact: Sherry James Corporate Sales Specialist, U.S.A. Grand View Research, Inc. United States Phone: 1-415-349-0058 Toll Free: 1-888-202-9519 Email: [email protected] Website: Grand View Research Blog Site: http://www.mediafound.org/
0 Comments
The rising prevalence of chronic diseases such as diabetes coupled with rise in the diabetic population globally are the key factors driving the pen needles market. The increasing demand for safety injections has led to the technological advances in the market. As of 2013, the standard needle segment covered the largest revenue share in the market. The cost effectiveness of standard needles is the major factor towards the growth of this segment. Safety needles are presumed to grow rapidly over the next six years.
Request TOC of “Pen Needles Market Research Reports" visit - http://www.grandviewresearch.com/industry-analysis/pen-needles-market/request-toc The insulin therapy segment has witnessed a high growth in 2013 and is expected to sustain its high growth rate during the forecast period owing to increasing incidences of pancreas dysfunction in the body. The 6mm pen needle is expected to cover largest revenue share over the next six years owing to the increased use and adjustability of this needles. The 4mm needles are expected to grow rapidly during the forecast period. Europe dominates the pen needles market. The beneficial share of this region is due to the increasing incidences of diabetes coupled with the favorable recompensement scenario. North America is expected to witness the fastest growth over coming six years. Asia Pacific is expected to achieve leadership position in terms of value owing to the increasing patient awareness levels and increasing incidences of needlestick injuries in this region. The major market players includes Ultimed Inc, Owen Mumford Ltd., Allinson Medical Inc., Terumo Corporation, Artsana S.p.a, HTL Strefa S.A, Ypsomed Holding AG, Becton, B. Braun Melsungen AG, Dickinson and Company and Novo Nordisk. For More Information visit - http://www.grandviewresearch.com/industry-analysis/pen-needles-market The increasing incidences of lifestyle based diseases due to excessive drinking and smoking habits coupled with rising incidences of chronic diseases such as kidney tumors and kidney cancer has led to growth in the kidney cancer drugs market. The increasing geriatric population base globally is also the factor expected to further boost the growth of this market as they are more prone to chronic diseases. Additionally, the patients as well as clinicians prefer kidney cancer drugs over the targeted therapies. For the advanced stage metastatic tumor patients, cancer drugs are life saving and prolonging treatment regimens.
Nexavar is expected to have the largest share in the market owing to its common usage in several diseases during the forecast period. The different brands used as kidney cancer drugs are Inlyta (Axitnib), Nexavar (Sorafebin), Afinitor (Everolimus), Avastin (Bevaciazumab), Votrient (Pazopanib), Torisel (temosirolimus), Sutent and Proleukin (Interlukin-2/ Aldesleukin). It also combines the pipeline analysis for various potential drugs which are currently in phase II and phase III trials.. On the basis of region, the North America dominates the kidney cancer drugs market. The largest share of this region is due to the rising incidences of cancer and other kidney diseases. However, Asia Pacific is expected to witness a huge rise in the market share due to the low costs of drug production and increasing renal cell carcinoma patient base in this region. Various companies are creating their marketing strategies such as collaborations, expansions and new innovations to maintain their market share in the kidney cancer drugs market. The actively participating key players in the kidney cancer drugs market include Hoffman La Roche, Bayer Pharma AG, Glaxosmith, plc., Pfizer Inc., and Novartis AG. For More Information on “Kidney Cancer Drugs Market Research Reports" visit - http://www.grandviewresearch.com/industry-analysis/kidney-cancer-drugs-market The global cardiac prosthetic devices market is expected to grow at a considerable rate in the coming six years. A growing population base more prone to chronic cardiac conditions and rising mortality rates due to sudden cardiac arrests are expected to be the primary drivers for this growth. The efficiency of implantable pacemakers and stentless valves in treating cardiac arrhythmia and chronic cardiac conditions is also expected to fuel the demand for this market through to 2020.
For More Information on "Cardiac Prosthetic Devices Market Research Reports" visit - http://www.grandviewresearch.com/industry-analysis/cardiac-prosthetic-devices-market Cardiac prosthetic products include single, dual, triple chamber implantable & external pacemakers, mechanical heart valves, transcatheter, stented and stentless pulmonary and aortic tissue valves. The shift in focus of cardio logical surgeons towards heart valve reconstruction surgeries using pulmonary and stentless heart valves are the major reason for their large share of the generated market revenue for 2013. Further development of allograft and autograft heart valves will also fuel market demand as they have been proven to have a greater efficacy than conventional methods. The cardiac prosthetic devices market is geographically divided into North America, Europe, Asia Pacific and RoW. The largest share of revenue for 2013 was generated by North America. Driving factors for the North America cardiac prosthetic device market are the presence of an increasing aging population more prone to cardiac ailments, reinforced cardiac reimbursement policy framework and development of novel products aimed to reduce post surgery rejection rates. Asia Pacific region is expected to witness considerable growth throughout the forecast period due to rapid growth in development of medical infrastructure. The major participants in the global cardiac prosthetic devices market are Siemens Healthcare, Edward Lifesciences Corp., AtriCure Inc., Abbott Laboratories, St. Jude Medical Inc., Sorin Group, Medtronic Inc., Boston Scientific Corp. and Abiomed. Request TOC of “Cardiac Prosthetic Devices Market Research Reports" visit - http://www.grandviewresearch.com/industry-analysis/cardiac-prosthetic-devices-market/request-toc About Grand View Research Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy. Contact: Sherry James Corporate Sales Specialist, U.S.A. Grand View Research, Inc. United States Phone: 1-415-349-0058 Toll Free: 1-888-202-9519 Email: [email protected] Website: Grand View Research Blog Site: http://marketshare.blog.com/ Deep Brain Stimulators (DBS) Market Trends, Growth Prospects To 2020: Grand View Research, Inc.2/23/2015 Global deep brain stimulators market is expected to reach USD 1.59 billion by 2020, according to a new study by Grand View Research, Inc. Increasing incidence rates of target neurological disorders such as Parkinson’s and demand for minimally invasive surgical procedures are some primary factors expected to drive the deep brain stimulators market. Deep brain stimulators have witnessed a significant rise in usage rates and are now considered viable substitutes to conventional therapies. Higher efficacy exhibited by the former is a key reason attributing to the aforementioned conclusion. Introduction of technological advancements such as fractionation of electric current and selective current steering are also expected to improve device usage rates.
Deep brain stimulators are FDA approved when it comes to treating Parkinson’s, dystonia and OCD (obsessive compulsive disorder) etc. Moreover, the use of these devices for diseases such as trigeminal neuralgia, Tourette syndrome, Alzheimer’s, refractory epilepsy, cluster headache and movement disorders by multiple sclerosis are awaiting FDA approval. The potential inclusion of new application areas is expected fuel the future growth of the market. View summary of this report @ http://www.grandviewresearch.com/industry-analysis/deep-brain-stimulators-dbs-market Further key findings from the study suggest: • Parkinson’s disease was the largest application segment of the market in 2013. Use of deep brain stimulators for treating this disease renders symptomatic relief from medicine induced dyskinesia and therefore, these devices are expected to witness a rapid growth in demand during the forecast period. • OCD (obsessive compulsive disorder) was also one of the leading application segments in 2013. DBS has proven to be the most efficient treatment option pertaining to OCD and is expected to witness a rapid growth in usage rates over the next six years. • North America was the largest regional market, accounting for over 50.0% of market share in 2013. Presence of sophisticated healthcare infrastructure and reimbursement policies and increasing awareness levels of patients and healthcare personnel are some key factors expected to drive regional market growth during the forecast period. • Asia Pacific is identified as the most lucrative market. Rapidly improving healthcare infrastructure, presence of high unmet medical needs and increasing healthcare spending levels in the emerging markets of China and India are some factors attributing to its growth. • Some key manufacturers of deep brain stimulators include St. Jude Medical, Medtronic Plc, Boston Scientific Corporation and Aleva Neurotherapeutics SA. • The market is marked by the presence of extensive R&D investments targeting the development of technologically advanced systems catering to new application areas. Moreover, manufacturers participate in endeavors directed towards capitalizing on the untapped opportunities available in the emerging Asia Pacific and Latin American markets. About Grand View Research Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy. Contact: Sherry James Corporate Sales Specialist, U.S.A. Grand View Research, Inc. United States Phone: 1-415-349-0058 Toll Free: 1-888-202-9519 Email: [email protected] Website: Grand View Research Blog Site: http://www.divog.org/ Increasing incidence rates of atherosclerosis, heart valve issues, arrhythmias, diabetes and cardiomyopathy are some key factors driving demand for congestive heart failure treatment devices in coming six years. Approximately 5.1 million people in the U.S. have heart failure. Lifestyle habits such as smoking, lack of physical activity, unhealthy dietary habits are also increasing the incidences of congestive heart failure. Moreover, increasing geriatric population base is also expected to fuel the prevalence of congestive heart failure thereby propelling growth of this market in the forecast period.
For More Information on "Congestive Heart Failure Treatment Devices Market Research Reports" visit – http://www.grandviewresearch.com/industry-analysis/congestive-heart-failure-treatment-devices-market Cardiac assist devices (CAD) held one of the largest shares in congestive heart failure treatment devices market due to the shortage of heart donors and technologically advanced cardiac assist devices in 2013. Additionally, reimbursement coverage for cardiac device implantation procedures is anticipated to provide this segment with growth platform. North America dominated the overall market in terms of revenue owing to the increasing incidence rates of high blood pressure, arthritis, coronary artery disease leading to congestive heart failure. Moreover increasing patient awareness and improved healthcare infrastructure in the U.S. and Canada are expected to drive the market of this region at a rapid rate. Asia pacific market is expected to be the fastest growing market over the next six years. Increasing geriatric population base, presence of high unmet needs and untapped opportunity in emerging countries such as China and India are some drivers contributing to the growth of Asia Pacific market. Key market players of congestive heart failure treatment devices market are Boston Scientific, World Heart Corporation, St. Jude Medical Inc, Thoratec, cardioelectronica, Baikal, Medtronic Inc., Berlin Heart Inc., AbioMed, Placetronix and Jarvik Heart. Request TOC of “Congestive Heart Failure Treatment Devices Market Research Reports" visit - http://www.grandviewresearch.com/industry-analysis/congestive-heart-failure-treatment-devices-market/request-toc About Grand View Research Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy. Contact: Sherry James Corporate Sales Specialist, U.S.A. Grand View Research, Inc. United States Phone: 1-415-349-0058 Toll Free: 1-888-202-9519 Email: [email protected] Website: Grand View Research Blog Site: http://www.mediafound.org/ |